| Species |
Human |
| Protein Construction |
HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer[Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and RMFPNAPYL peptide]
Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&RMFPNAPYL |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human at 2μg/ml (100μl/well) on the plate can bind AntiHLAA*02:01&B2M&WT1 (RMFPNAPYL) Antibody, hFc Tag. Test result was comparable to standard batch |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
50.5 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 52-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1. |
| Synonyms |
MHC; WT1; RMF; AWT1; GUD; NPHS4GUD; WAGR; WIT-2; WT33 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
